BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Applied DNA Sciences, Inc. (APDN) Announces Webcast: Mandate for SigNature® DNA Marking. Learn the Facts.


12/12/2012 9:06:44 AM

STONY BROOK, NY--(Marketwire - December 12, 2012) - Applied DNA Sciences, Inc. (OTCBB: APDN), (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today that it will host a free webcast entitled: "The Mandate for DNA Marking, Compliance with Section 818 of the National Defense Authorization Act, and the Future of Electronics Security." The webinar will take place on Friday, December 14, 2012 at 11 AM EST.

The company has advertised:

"Discover the facts, the technology, the how-to directly from the company which developed the anti-counterfeiting platform: Applied DNA Sciences."

You may reserve your Webinar seat now at:
https://www3.gotomeeting.com/register/904581334

Experts say that SigNature DNA marking presents a simple, proactive approach to help protect the military and commercial supply chain. Selected by the Defense Logistics Agency after an eighteen-month pilot program at commercial scale, vetted by national labs and tested at CALCE, the technology is now required by Defense Logistics Agency for parts that fall into category FSC 5962 (microcircuits). The mandate has been linked by DLA to the all-important anti-counterfeiting measures taken in Section 818 of the National Defense Authorization Act for Fiscal Year 2012, an industry-changing initiative.

The company promises the webcast will present "the plain facts, without the politics."

Topics:

  • What makes SigNature DNA marks unbreakable and uncopyable
  • Why SigNature DNA marks may not be successfully transferred
  • How recent studies support the stability of the mark
  • How DNA marking will be used by distributors
  • How to mitigate counterfeit risk on legacy parts
  • How DNA marking applies to existing inventory
  • Open discussion of cost and logistical considerations

Dr. James A. Hayward, CEO and President of Applied DNA Sciences, stated,

"We are proud that our security platform has earned the trust of the Defense Logistics Agency and that our solution has been welcomed by industry thought-leaders. Most importantly, we are honored that we can contribute in any way to the protection of our warfighters. I believe listeners will benefit greatly from our presentation."

About Applied DNA Sciences

APDN is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA and smartDNA, our principal anti-counterfeiting and product authentication solutions that essentially cannot be copied, provide a forensic chain of evidence and can be used to prosecute perpetrators.

The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 8, 2011 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.


MEDIA CONTACT:
Mitchell Miller
646-543-3373
fax: 631-444-8848

INVESTOR CONTACT:
Debbie Bailey
631-444-8090
fax: 631-444-8848

FCMN Contact: Email Contact

Web site: http://www.adnas.com
Twitter: @APDN, @APDNInvestor


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->